Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1392705

A Study of Pre-and Post-Treatment Hematologic Markers of Immune Response in Patients Undergoing Radiotherapy for Soft Tissue Sarcoma

Provisionally accepted
Eric Ku Eric Ku 1*Garrett Harada Garrett Harada 1Grace Lee Grace Lee 2Akul Munjal Akul Munjal 1Nicholas Peterson Nicholas Peterson 1Jino Park Jino Park 1Warren Chow Warren Chow 3Russell Stitzlein Russell Stitzlein 4Charles Limoli Charles Limoli 1Jeremy Harris Jeremy Harris 1
  • 1 Department of Radiation Oncology, School of Medicine, University of California, Irvine, Irvine, California, United States
  • 2 School of Medicine, University of California, Irvine, Irvine, California, United States
  • 3 Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of California, Irvine, Orange, California, United States
  • 4 Department of Orthopaedic Surgery, School of Medicine, University of California, Irvine, Orange, California, United States

The final, formatted version of the article will be published soon.

    outcomes in soft tissue sarcoma (STS) patients undergoing radiation therapy (RT).Data from 64 patients who underwent RT for curative management of STS were reviewed. Pre-RT and post-RT hematologic measures were evaluated for associations with survival outcomes. A normal tissue complication probability (NTCP) curve for predicting ΔPLR ≥ 75 was modeled using a probit function.Elevated baseline NLR was associated with worse overall survival (OS) and disease-free survival (DFS), while elevated PLR was associated with worse DFS. Post-RT, elevated PLR was linked to worse OS and DFS. Increasing PLR change post-RT was associated with worse OS and DFS. Receiver operating characteristics analysis determined ΔPLR ≥ 75 to be a robust cutoff associated with worse DFS. Bone V10Gy ≥362 cc corresponded to a 50% risk of developing ΔPLR ≥ 75.These results suggest that hematologic markers could serve as prognostic biomarkers in both pre-and post-treatment settings for STS patients undergoing RT. Future studies can consider using bone V10Gy < 362 cc as a potential cutoff to reduce the risk of increased PLR after RT.

    Keywords: sarcoma1, radiation2, NLR3, PLR4, dosimetry5

    Received: 27 Feb 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Ku, Harada, Lee, Munjal, Peterson, Park, Chow, Stitzlein, Limoli and Harris. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Eric Ku, Department of Radiation Oncology, School of Medicine, University of California, Irvine, Irvine, CA 92868-3298, California, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.